JP2014516924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516924A5 JP2014516924A5 JP2014504013A JP2014504013A JP2014516924A5 JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5 JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- viscosity
- less
- citrate
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473121P | 2011-04-07 | 2011-04-07 | |
| US61/473,121 | 2011-04-07 | ||
| PCT/US2012/032462 WO2012138958A1 (en) | 2011-04-07 | 2012-04-06 | Formulations with reduced viscosity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516924A JP2014516924A (ja) | 2014-07-17 |
| JP2014516924A5 true JP2014516924A5 (enExample) | 2016-01-28 |
Family
ID=46969561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504013A Pending JP2014516924A (ja) | 2011-04-07 | 2012-04-06 | 粘度が低減された処方物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140023655A1 (enExample) |
| EP (2) | EP2694100A4 (enExample) |
| JP (1) | JP2014516924A (enExample) |
| KR (1) | KR20140018966A (enExample) |
| CN (1) | CN103596585A (enExample) |
| AU (2) | AU2012240050B2 (enExample) |
| BR (1) | BR112013025866A2 (enExample) |
| CA (1) | CA2832556A1 (enExample) |
| EA (1) | EA201391488A1 (enExample) |
| IL (1) | IL228591A0 (enExample) |
| SG (1) | SG193963A1 (enExample) |
| WO (1) | WO2012138958A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2523688T1 (en) * | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| WO2014141149A1 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| WO2014169153A1 (en) * | 2013-04-10 | 2014-10-16 | Echogen, Inc. | Peptide complexes and therapeutic uses |
| JP6179939B2 (ja) * | 2013-07-09 | 2017-08-16 | 国立大学法人 筑波大学 | 高濃度γグロブリン製剤の粘度低下方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| EP3256147B8 (en) * | 2015-01-18 | 2020-10-21 | Gloriana Therapeutics, Inc. | Therapeutic protein formulations |
| ES3053874T3 (en) * | 2015-08-24 | 2026-01-27 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| JP7641908B2 (ja) | 2019-03-29 | 2025-03-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 |
| CA3187322A1 (en) * | 2020-07-13 | 2022-01-20 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations |
| KR20230167968A (ko) * | 2022-06-03 | 2023-12-12 | 주식회사 녹십자홀딩스 | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5747447A (en) * | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| DE60139944D1 (de) * | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| CA2503871C (en) * | 2002-11-01 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | An immunogenic composition for generating an immune response against polio virus |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP2129401B8 (en) * | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| AU2008304111B2 (en) * | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| TW200944231A (en) * | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SI2523688T1 (en) * | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| DK2531218T3 (en) * | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
-
2012
- 2012-04-06 BR BR112013025866A patent/BR112013025866A2/pt not_active IP Right Cessation
- 2012-04-06 EP EP12768307.6A patent/EP2694100A4/en not_active Withdrawn
- 2012-04-06 CN CN201280026486.5A patent/CN103596585A/zh active Pending
- 2012-04-06 CA CA2832556A patent/CA2832556A1/en not_active Abandoned
- 2012-04-06 US US14/110,182 patent/US20140023655A1/en not_active Abandoned
- 2012-04-06 KR KR1020137029163A patent/KR20140018966A/ko not_active Withdrawn
- 2012-04-06 JP JP2014504013A patent/JP2014516924A/ja active Pending
- 2012-04-06 WO PCT/US2012/032462 patent/WO2012138958A1/en not_active Ceased
- 2012-04-06 EA EA201391488A patent/EA201391488A1/ru unknown
- 2012-04-06 SG SG2013072426A patent/SG193963A1/en unknown
- 2012-04-06 AU AU2012240050A patent/AU2012240050B2/en not_active Ceased
- 2012-04-06 EP EP16154327.7A patent/EP3058952A1/en not_active Withdrawn
-
2013
- 2013-09-29 IL IL228591A patent/IL228591A0/en unknown
-
2016
- 2016-04-14 AU AU2016202355A patent/AU2016202355A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510152A5 (enExample) | ||
| KR102462041B1 (ko) | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 | |
| CN108883178B (zh) | 含抗体制剂 | |
| RU2020123963A (ru) | Стабилизированные препараты, содержащие антитела против ngf | |
| ES2885815T3 (es) | Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento | |
| JP2022087255A (ja) | キャリア結合剤組成物およびそれを作製および使用する方法 | |
| JP2021059593A (ja) | 担体および抗体からなる組成物およびその製造および使用方法 | |
| JP2019503349A5 (enExample) | ||
| RU2013155695A (ru) | Препараты антител против с-мет | |
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| JP2018521135A5 (enExample) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| JP2014522843A5 (enExample) | ||
| NZ630020A (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| JP2020537520A5 (enExample) | ||
| UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| US20230203152A1 (en) | Engineered anti-il-2 antibodies | |
| RU2016129624A (ru) | Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера | |
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| JP2019506841A5 (enExample) | ||
| JP2013543505A5 (enExample) | ||
| RU2014143639A (ru) | Регулируемые протеазой антитела |